Moderna (Germany) Performance

0QF Stock  EUR 31.60  1.10  3.61%   
On a scale of 0 to 100, Moderna holds a performance score of 10. The company secures a Beta (Market Risk) of 0.34, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Moderna's returns are expected to increase less than the market. However, during the bear market, the loss of holding Moderna is expected to be smaller as well. Please check Moderna's downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Moderna's current price movements will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Moderna are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Moderna reported solid returns over the last few months and may actually be approaching a breakup point. ...more
  

Moderna Relative Risk vs. Return Landscape

If you would invest  2,320  in Moderna on October 11, 2025 and sell it today you would earn a total of  840.00  from holding Moderna or generate 36.21% return on investment over 90 days. Moderna is currently producing 0.633% returns and takes up 4.7394% volatility of returns over 90 trading days. Put another way, 42% of traded stocks are less volatile than Moderna, and 88% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Moderna is expected to generate 6.74 times more return on investment than the market. However, the company is 6.74 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of risk.

Moderna Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Moderna's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moderna, and traders can use it to determine the average amount a Moderna's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1336

High ReturnsBest Equity
Good Returns
Average Returns
Small Returns0QF
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 4.74
  actual daily
42
58% of assets are more volatile

Expected Return

 0.63
  actual daily
12
88% of assets have higher returns

Risk-Adjusted Return

 0.13
  actual daily
10
90% of assets perform better
Based on monthly moving average Moderna is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moderna by adding it to a well-diversified portfolio.

Moderna Fundamentals Growth

Moderna Stock prices reflect investors' perceptions of the future prospects and financial health of Moderna, and Moderna fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moderna Stock performance.

About Moderna Performance

By analyzing Moderna's fundamental ratios, stakeholders can gain valuable insights into Moderna's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Moderna has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Moderna has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people.

Things to note about Moderna performance evaluation

Checking the ongoing alerts about Moderna for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moderna help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Moderna appears to be risky and price may revert if volatility continues
About 68.0% of the company shares are owned by institutions such as pension funds
Evaluating Moderna's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Moderna's stock performance include:
  • Analyzing Moderna's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moderna's stock is overvalued or undervalued compared to its peers.
  • Examining Moderna's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Moderna's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moderna's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Moderna's stock. These opinions can provide insight into Moderna's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Moderna's stock performance is not an exact science, and many factors can impact Moderna's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Moderna Stock analysis

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies